Overview

Foxiga Korea Local Phase 4 Study

Status:
Completed

Trial end date:
2018-01-15

Target enrollment:

Participant gender:

Summary

To evaluate the effect of dapagliflozin on body composition in Korean T2DM subjects.12-month, randomised, open-label, parallel-group, multi-centre phase IV study.

Phase:

Phase 4

Details

Lead Sponsor:

AstraZeneca

Treatments:

Dapagliflozin
Glimepiride
Metformin